Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MAZE with free AI briefings, catalyst countdowns, and dilution alerts.

MAZE · Maze Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$477M Cash on Hand
59.8mo Cash Runway
Follow MAZE by email Get an email when MAZE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MAZE, unsubscribe in one click. Privacy

📣 What MAZE Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
MZE782 Phenylketonuria (PKU) Phase 2 · NCT07694440 Recruiting
MZE829 Proteinuric Kidney Disease Phase 2 · NCT06830629 Recruiting
MZE001 Healthy Phase 1 · NCT05249621 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MAZE holds $477M in cash and short-term investments (as of Sep 30, 2026) and burns about $23.9M/quarter from operations, an estimated runway of 59.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 22 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MAZE files for a raise →

👥 Who Owns MAZE

Insiders 0.5% Other 5%+ holders 14.8% Institutions (220 holders) 84.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
Frazier Life Sciences Public Fund, L.P. 5%+ holder (13G) 4,342,266 7.94% 2025-12-31
Third Rock Ventures IV, L.P. 5%+ holder (13G) 3,723,958 6.81% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 2,978,114 5.45% 2026-06-30
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 2,858,876 5.23% 2026-03-31
Jason V Coloma
Chief Executive Officer, Director · +50,000 options
Insider 199,866 0.37% 2026-11-02
Atul Dandekar
CSBO · +85,502 options
Insider 32,316 0.06% 2026-10-29
Charles J Homcy
Director · +18,000 options
Insider 31,113 0.06% 2026-05-04
Phillips Courtney
GC and Corp. Secretary · +11,000 options
Insider 7,007 0.01% 2026-09-02

Share count 54,683,345 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MAZE picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MAZE and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.